A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Tislelizumab
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

BeiGene